DR. MARIA LUISA CALABRÒ
BIOLOGIST
- Role of the microenvironment in the pathogenesis of virus-induced lymphoma
- Relevance of epithelial-mesenchymal plasticity (EMP) in highly aggressive primary tumors and peritoneal metastases
PROF. VINCENZO CIMINALE
MD
- Harnessing redox homeostasis and cell death pathways for treatment of T-cell leukemia
DR. MATTEO CURTARELLO
BIOLOGIST, PHD
- Liquid biopsy (cell free DNA, cfDNA) approach to track tumor response to therapy and/or relapse in gastric esophageal oncologic diseases (GEODs)
DR. ANNAROSA DEL MISTRO
MD
- HPV testing and novel biomarkers in prevention and diagnosis of cervical and oropharyngeal HPV-driven carcinomas
DR. STEFANO INDRACCOLO
MD
- Metabolic adaptation of tumors to anti-angiogenic therapy
- Genetic profiling of lung cancer
- NOTCH as a therapeutic target in cancer
DR. CHIARA MENIN
BIOLOGIST
- Genetic risk factors for cutaneous melanoma
- Molecular classification of cutaneous melanoma and molecular markers for prediction of the targeted therapy response in the advanced melanoma
PROF. SIMONE MOCELLIN
MD, PHD
- PD1 and PDL1 expression as therapeutic targets and prognostic biomarkers in soft tissue sarcomas
- Clock genes polymorphisms as risk and prognostic factors in melanoma and soft tissue sarcomas
DR. ERICH PIOVAN
MD, PHD
- Targeted therapeutic approaches in T cell acute lymphoblastic leukemia (T-ALL) and Diffuse Large B-cell lymphoma (DLBCL)
DR. VALERIA TOSELLO
BIOLOGIST
- Molecular pathogenesis of T-cell acute lymphoblastic leukaemia and lymphoma
Gruppi di ricerca
CLINICAL RESEARCH GROUP ON BREAST CANCER
ONCOLOGY 2 UNIT
- Tailoring the treatment in early breast cancer
- Immunotherapy in breast cancer
- Identifying prognostic and predictive biomarkers in breast cancer
GASTROINTESTINAL CANCERS CLINICAL RESEARCH GROUP
ONCOLOGY 1 UNIT
- Development of tailored treatment: one size do not fits all
- Multidisciplinary approach to the disease
- New targets for new treatment
- Immunotherapy is the new frontier
GENITO URINARY ONCOLOGY RESEARCH TEAM
ONCOLOGY 1 UNIT
- Biomarkers and treatment of patients with Prostate cancer
- Biomarkers and Treatment of patients with Renal cell carcinoma
- Immunotherapy and biomarkers in patients with Bladder or Upper Urinary Tract carcinoma
- Outcome and quality of life of patients with Testicular cancer
GYNECOLOGIC ONCOLOGY CLINICAL RESEARCH GROUP
ONCOLOGY 2 UNIT
- Multidisciplinary approach to the disease
- Immunotherapy is the new frontier
- Real word evidence studies
HEAD AND NECK CANCERS CLINICAL RESEARCH TEAM
ONCOLOGY 2 UNIT
- Improving the treatment strategies and identifying new prognostic and predictive biomarkers
NETWORK CLINICAL RESEARCH GROUP
ONCOLOGY 2 UNIT
- Evaluation of the impact of the diagnostic-therapeutic pathways in oncology
- Regional and National collection of real world data on activity, efficacy, safety and budget impact of innovative anticancer drugs
- Regional and National prospective clinical studies
- Administrative health data extraction on diagnosis and treatment of breast and lung cancer
NEURO-ONCOLOGY RESEARCH TEAM
ONCOLOGY 1 UNIT
- Developing novel therapeutics for the treatment of malignant brain tumors
- Identifying the right treatment for elderly patients with brain tumors improving their quality of life and neuro-cognitive functions
- Identifying molecular predictors of treatment benefit in glioblastoma patients
- New imaging modalities in early disease detection and response assessment to new therapies in glioblastoma patients
ONCO-HAEMATOLOGICAL RESEARCH TEAM
ONCOLOGY 1 UNIT
- New therapeutic approach in lymphoma
- Diffuse large B cell lymphoma in elderly patients
- Molecular prognostic factors in Diffuse Large B cell lymphoma
SARCOMA RESEARCH TEAM
ONCOLOGY 1 UNIT
- Developing novel therapeutics for the treatment of soft tissue sarcoma and bone tumors
- Multidisciplinary approach to the disease
- Identifying the optimal treatment for older patients with advanced soft tissue sarcoma
- Identifying molecular predictors of treatment benefit in patients with sarcoma
THORACIC MALIGNANCIES CLINICAL RESEARCH TEAM
ONCOLOGY 2 UNIT
- Improvement of multidisciplinary management of lung cancer, mesothelioma and thymic neoplasms
- Access to wide molecular characterization and targeted treatment in lung cancer
- Implementation of liquid biopsy for lung cancer in clinical practice
- Study of predictive markers for immunotherapy efficacy and toxicity in lung cancer
- Study of predictive biomarkers and acquired resistance mechanisms in EGFR-mutated advanced NSCLC